

Supreme Pharmaceuticals

09:20 15 Jul 2016

Supreme Pharma closes second tranche of placement, raises \$4.34mIn

Supreme Pharmaceuticals Inc. (CNSX:SL) closed the second tranche of its non-brokered private placement on Friday, raising \$723,250 and combined proceeds of \$4,339,130 as well as signalled a possible third tranche to come.

Supreme Pharmaceuticals develops an in-licensed technology aimed at targeting obesity.

In June the company made its first MMPR (marijuana for medical purposes regulations) revenue, it told investors. **Read more.**

Upon closure, the company issued 1,808,125 units at a price of 40 cents per unit. Each unit consists of one common share and one common share purchase warrant. Each warrant is exercisable for one common share of the corporation at a price of 50 cents for a period of three years from closing.

The common shares and warrants issued are subject to a hold period that expires Nov. 15, 2016. The company paid aggregate finders' fees of \$12,750 and issued 24,375 warrants to certain participating dealers in connection with the financing.

The company will use net proceeds of the financing for the expansion of the company's Kincardine hybrid greenhouse facility and for general working capital purposes. The company may complete a third tranche of the financing.

In addition, Supreme said it has entered into a sixth letter of intent (LOI) with respect to the long-term supply of dried cannabis to a licensed producer (as such term is defined in the marijuana for medical purposes regulations).

The LOI is on the same terms and subject to the same conditions as the company's initial five LOIs announced on May 20, 2015.

Share Information

Code: SL

Listing: CNSX

Sector: Pharma & Biotech

Website:

www.supremepharmaceuticals.com

Company Synopsis:

Supreme Pharmaceuticals Inc. is a Company that is dedicated to providing and developing an in-licensed technology with an IP portfolio aimed at targeting Obesity. The platform will address the fundamental changes in healthcare and enabling relief for millions people in Obesity. In addition, the company is also pursuing opportunities in the Medical Marijuana Industry.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.